ChemoMetec - Public Comps and Valuation Multiples

ChemoMetec Overview

About ChemoMetec

ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.

Founded

1997

HQ

Employees

170

Website

chemometec.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $79.6M

LTM EBITDA $41.3M

EV

$1.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ChemoMetec Financials

As of August 2025, ChemoMetec reported last 12-month revenue of $79.6M and EBITDA of $41.3M.

In the same period, ChemoMetec generated $61.9M in LTM gross profit and $30.2M in net income.

See ChemoMetec valuation multiples based on analyst estimates

ChemoMetec P&L

In the most recent fiscal year, ChemoMetec reported revenue of $77.4M and EBITDA of $40.9M.

ChemoMetec expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ChemoMetec valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$79.6M	XXX	$77.4M	XXX	XXX	XXX
Gross Profit	$61.9M	XXX	$72.7M	XXX	XXX	XXX
Gross Margin	78%	XXX	94%	XXX	XXX	XXX
EBITDA	$41.3M	XXX	$40.9M	XXX	XXX	XXX
EBITDA Margin	52%	XXX	53%	XXX	XXX	XXX
EBIT	$37.8M	XXX	$36.9M	XXX	XXX	XXX
EBIT Margin	47%	XXX	48%	XXX	XXX	XXX
Net Profit	$30.2M	XXX	$29.1M	XXX	XXX	XXX
Net Margin	38%	XXX	38%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for ChemoMetec including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $79.6M. EBITDA for the last twelve months was $41.3M. In the most recent fiscal year, ChemoMetec achieved $77.4M in revenue and $40.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$79.6M	Analyst estimates available to subscribers	$77.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$61.9M	Analyst estimates available to subscribers	$72.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	77.8% gross margin	Analyst estimates available to subscribers	93.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$41.3M	Analyst estimates available to subscribers	$40.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	51.9% EBITDA margin	Analyst estimates available to subscribers	52.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$37.8M	Analyst estimates available to subscribers	$36.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	47.5% EBIT margin	Analyst estimates available to subscribers	47.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$30.2M	Analyst estimates available to subscribers	$29.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	37.9% net profit margin	Analyst estimates available to subscribers	37.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for ChemoMetec

This financial data table provides comprehensive performance metrics for ChemoMetec, a company based in Denmark. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

ChemoMetec generated $79.6M in revenue over the last twelve months.
The company achieved $41.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $61.9M.
Net income over the last twelve months reached $30.2M.

Fiscal Year Performance

In the most recent fiscal year, ChemoMetec reported $77.4M in total revenue.
Fiscal year EBITDA was $40.9M.
The company maintained a gross profit margin of 93.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 52.9%.
Net profit margin reached 37.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for ChemoMetec. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

ChemoMetec Stock Performance

ChemoMetec has current market cap of DKK 11.0B (or $1.7B), and EV of DKK 10.7B (or $1.7B).

Market Cap Evolution

ChemoMetec Stock Data

As of September 17, 2025, ChemoMetec's stock price is DKK 631 (or $99).

See ChemoMetec trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.7B	$1.7B	XXX	XXX	XXX	XXX	$1.70

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

ChemoMetec Valuation Multiples

ChemoMetec's trades at 23.6x EV/Revenue multiple, and 46.7x EV/EBITDA.

See valuation multiples for ChemoMetec and 15K+ public comps

ChemoMetec Financial Valuation Multiples

As of September 17, 2025, ChemoMetec has market cap of $1.7B and EV of $1.7B.

Equity research analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ChemoMetec has a P/E ratio of 56.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV/Revenue	20.9x	XXX	23.6x	XXX	XXX	XXX
EV/EBITDA	40.3x	XXX	46.7x	XXX	XXX	XXX
EV/EBIT	44.0x	XXX	52.6x	XXX	XXX	XXX
EV/Gross Profit	26.9x	XXX	n/a	XXX	XXX	XXX
P/E	56.9x	XXX	68.1x	XXX	XXX	XXX
EV/FCF	75.4x	XXX	93.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ChemoMetec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

ChemoMetec Margins & Growth Rates

ChemoMetec's last 12 month revenue growth is 14%

ChemoMetec's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

ChemoMetec's rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ChemoMetec's rule of X is 87% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for ChemoMetec and other 15K+ public comps

ChemoMetec Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	14%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	52%	XXX	50%	XXX	XXX	XXX
EBITDA Growth	23%	XXX	23%	XXX	XXX	XXX
Rule of 40	65%	XXX	65%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	87%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	46%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial